missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human DGCR2 (aa 455-549) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (83%), Rat (83%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-67399 (PA5-67399. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Deletions of the 22q11.2 have been associated with a wide range of developmental defects (notably DiGeorge syndrome, velocardiofacial syndrome, conotruncal anomaly face syndrome and isolated conotruncal cardiac defects) classified under the acronym CATCH 22. The DGCR2 gene encodes a novel putative adhesion receptor protein, which could play a role in neural crest cells migration, a process which has been proposed to be altered in DiGeorge syndrome.
Specifications
Specifications
| Accession Number | P98153 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 9993 |
| Name | Human DGCR2 (aa 455-549) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 9930034O06Rik; Dgcr2; Dgsc; DGS-C; DiGeorge syndrome critical region gene 2; DiGeorge syndrome critical region protein 2; DiGeorge syndrome gene c; DiGeorge syndrome protein C; IDD; integral membrane protein deleted in DiGeorge syndrome; integral membrane protein DGCR2/IDD; KIAA0163; Lan; mKIAA0163; seizure-related membrane-bound adhesion protein; Sez12; Sez-12 |
| Common Name | DGCR2 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction